Transforming growth factor-β and ischemic brain injury

被引：84

作者：

Alain Buisson ^{[1
]}

Sylvain Lesne ^{[1
]}

Fabian Docagne ^{[1
]}

Carine Ali ^{[1
]}

Olivier Nicole ^{[1
]}

Eric T. MacKenzie ^{[1
]}

Denis Vivien ^{[1
]}

机构：

[1] Université de CAEN, UMR CNRS 6551, Centre CYCERON, Caen Cedex, bd H. Becquerel

[2] Universite de CAEN-CNRS UMR 6551, Centre CYCERON, IFR 47

来源：

Cellular and Molecular Neurobiology | 2003年 / 23卷 / 4-5期

关键词：

Cerebral ischemia; Molecular; TGF-β;

D O I：

10.1023/A:1025072013107

中图分类号：

学科分类号：

摘要：

1. Necrosis and apoptosis are the two fundamental hallmarks of neuronal death in stroke. Nevertheless, thrombolysis, by using the recombinant serine protease t-PA, remains until now the only approved treatment of stroke in man. 2. Over the last years, the cytokine termed Transforming Growth Factor-β1 (TGF-β1) has been found to be strongly up-regulated in the central nervous system following ischemia-induced brain damage. 3. Recent studies have shown a neuroprotective activity of TGF-β1 against ischemia-induced neuronal death. In vitro, TGF-β1 protects neurons against excitotoxicity by inhibiting the t-PA-potentiated NMDA-induced neuronal death through a mechanism involving the up-regulation of the type-1 plasminogen activator inhibitor (PAI-1) in astrocytes. 4. In addition, TGF-β1 has been recently characterized as an antiapoptotic factor in a model of staurosporine-induced neuronal death through a mechanism involving activation of the extracellular signal-regulated kinase 1/2 (Erk1/2) and a concomitant increase phosphorylation of the antiapoptotic protein Bad. 5. Altogether, these observations suggest that either TGF-β signaling or TGF-β1-modulated genes could be good targets for the development of new therapeutic strategies for stroke in man.

引用

页码：539 / 550

页数：11

共 53 条

[11] Flanders K.C., Ren R.F., Lippa C.E., Transforming growth factor-βs in neurodegenerative disease, Prog. Neurobiol., 54, pp. 71-85, (1998)
[12] Frautschy S.A., Horn D.L., Sigel J.J., Harris-White M.E., Mendoza J.J., Yang F., Saido T.C., Cole G.M., Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain, J. Neurosci., 18, pp. 8311-8321, (1998)
[13] Henrich-Noack P., Prehn J.H., Krieglstein J., TGF-β1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms, Stroke, 27, pp. 1609-1614, (1996)
[14] Hill I.E., Preston E., Monette R., MacManus J.P., A comparison of cathepsin-B processing and distribution during neuronal death in rats following global ischemia or decapitation necrosis, Brain Res., 751, pp. 206-216, (1997)
[15] Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P., Alamowitch S., Domenga V., Cecillion M., Marechal E., Maciazek J., Vayssiere C., Cruaud C., Cabanis E.A., Ruchoux M.M., Weissenbach J., Bach J.F., Bousser M.G., Tournier-Lasserve E., Notch3-mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia, Nature, 383, pp. 707-710, (1996)
[16] Kaufmann S.H., Hengartner M.O., Programmed cell death: Alive and well in the new millennium, Biology, 11, pp. 526-534, (2001)
[17] Krupinski J., Kumar P., Kumar S., Kaluza J., Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans, Stroke, 27, pp. 852-857, (1996)
[18] Lee J.M., Zipfel G.J., Choi D.W., The changing landscape of ischaemic brain injury mechanisms, Nature, 399, 6738 SUPPL., (1999)
[19] Lehrmann E., Kiefer R., Christensen T., Toyka K.V., Zimmer J., Diemer N.H., Hartung H.P., Finsen B., Microglia and macrophages are major sources of locally produced transforming growth factor-β1 after transient middle cerebral artery occlusion in rats, Glia, 24, pp. 437-448, (1998)
[20] Lesne S., Blanchet S., Docagne F., Liot G., Plawinski L., MacKenzie E.T., Auffray C., Buisson A., Pietu G., Vivien D., Transforming growth factor-β1-modulated cerebral gene expression, J. Cereb. Blood Flow Metab., 22, pp. 1114-1123, (2002)

← 1 2 3 4 5 6 →